Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.4591 +0.0209 (+4.77%)
Streaming Delayed Price Updated: 11:28 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
News headline image
Where Sangamo Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings for Sangamo Therapeutics ↗
 
Via Benzinga
News headline image
A Preview Of Sangamo Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
News headline image
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
News headline image
Earnings Scheduled For November 1, 2023 ↗
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
News headline image
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Mobile Infrastructure Corporation (NASDAQ: BEEP) shares jumped 98.7% to $12.02. 
Via Benzinga
News headline image
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases ↗
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday! 
Via InvestorPlace
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  During Wednesday's session, 212 companies made new 52-week lows. 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.